Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195260
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
2005-09-12
Brief Title:
Study Evaluating SKI-606 Bosutinib In Advanced Malignant Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase I Dose-Escalation Study Of Oral SKI-606 In Subjects With Advanced Malignant Solid Tumors
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of oral SKI-606 bosutinib administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose MTD in this subject population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B1871012 | None | None | None |